The Prof G Pod with Scott Galloway Office Hours: The Psychedelics Industry — with Ronan Levy
Dec 6, 2021
Ronan Levy, co-founder and executive chairman of Field Trip Health, dives into the evolving psychedelics industry. He discusses the resurgence of therapies like ketamine and psilocybin for mental health, highlighting their potential benefits when used in structured therapeutic settings. Listeners raise concerns about commercialization and ethics in psychedelics, prompting a thoughtful exploration of capitalism's impact. Finally, Ronan shares techniques for maintaining the transformative feelings of wonder that accompany psychedelic experiences.
AI Snips
Chapters
Transcript
Episode notes
Psychedelic Renaissance
- The psychedelics industry is experiencing a renaissance, with renewed research and increasing access to therapies.
- MDMA and psilocybin therapies are expected to be approved soon, marking a significant shift in mental healthcare.
Field Trip Health's Approach
- Field Trip Health focuses on providing psychedelic therapies, emphasizing the importance of "set and setting."
- They also develop psychedelic molecules with shorter durations for increased accessibility and affordability.
Different Psychedelics, Different Uses
- Ketamine, MDMA, and psilocybin are currently used for specific mental health conditions, but their applications may expand.
- Research suggests potential overlaps in their effectiveness for various conditions like depression and PTSD.